Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 7 14 28 versus SIMLIYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 7 14 28 versus SIMLIYA.
ORTHO-NOVUM 7/14-28 vs SIMLIYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Not available; SIMLIYA is a trademarked combination drug with no established mechanism of action.
One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.
Insulin glargine (SIMLIYA) is a long-acting insulin analog administered subcutaneously once daily. Typical starting dose for adults with type 2 diabetes is 0.2 units/kg or 10 units once daily, adjusted based on blood glucose targets. For type 1 diabetes, total daily dose is divided; basal insulin glargine typically constitutes 40-50% of total daily dose, given once daily.
None Documented
None Documented
Ethinyl estradiol: ~13-27 h (mean 17 h); Norethindrone: ~5-14 h (mean 8 h). Clinical context: steady-state achieved after ~5 days; half-life supports daily dosing.
Terminal elimination half-life is approximately 12 hours; clinically, steady state is achieved within 2-3 days of regular dosing.
Renal: ~50-60% (metabolites); biliary/fecal: ~30-40% (metabolites); unchanged drug <1% in urine.
Renal excretion of unchanged drug accounts for ~70% of elimination; biliary/fecal excretion accounts for ~25%, with the remainder as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive